meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
Trade name: MenQuadfi
Vaccineapproved
Approved
Apr 23, 2020
The Pilatus PC-7 Turbo Trainer is a low-wing tandem-seat training aircraft, designed and manufactured in Switzerland by Pilatus Aircraft. The aircraft is capable of all basic training functions, including aerobatics, instrument, tactical, and night flying. — Wikipedia
Clinical trial activity
200 trials · 65 clinical orgs · 1 marketing orgs
Phase 1
19
Phase 2
158
Phase 3
99
Phase 4
25
Earliest trial started Apr 1, 2002 (NCT00161928)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2002
Earliest Phase 3 Sponsor(trial)
- Jan 14, 2005
Sanofi-Aventis — First NDA Organization
- Jan 14, 2005
Sanofi-Aventis — NDA Secondary Org
- Jan 14, 2005
Sanofi-Aventis — NDA Organization
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
2020s
- Apr 23, 2020
Earliest FDA Approval
Indications
Approved for
Studied for
- Bacterial Infections · Phase 3
- Chickenpox · Phase 3
- Coronavirus · Phase 3
- Diarrhea · Phase 1/Phase 2
- Diphtheria · Phase 4
- Diphtheria-Tetanus-acellular Pertussis Vaccines · Phase 1
- Diphtheria-Tetanus-Pertussis Vaccine · Phase 3
- Dysentery, Bacillary · Phase 2
- Encephalitis, Japanese · Phase 3
- Gonorrhea · Phase 3
- Haemophilus Infections · Phase 1
- Haemophilus influenzae · Phase 4
- Haemophilus influenzae type b · Phase 3
- Healthy Volunteers · Phase 4
- Hemorrhagic Fever, Ebola · Phase 2
- Hepatitis B · Phase 3
- HIV · Phase 4
- HIV Infections · Phase 4
- Immunization · Phase 4
- Infections · Phase 3
- Influenza, Human · Phase 4
- Malaria · Phase 2
- Measles · Phase 3
- Meninges · Phase 3
- Meningitis · Phase 4
- Meningitis, Meningococcal · Phase 4
- Meningococcal Infections · Phase 4
- Meningococcal Vaccines · Phase 3
- Metapneumovirus · Phase 1
- Multiple Sclerosis · Phase 2
- Mumps · Phase 3
- Neisseria meningitidis · Phase 3
- Neoplasms, Glandular and Epithelial · Phase 3
- Papillomaviridae · Phase 4
- Papillomavirus Infections · Phase 3
- Pertussis Vaccine · Phase 4
- Pneumococcal Infections · Phase 3
- Rabies · Phase 3
- Respiratory Syncytial Viruses · Phase 1/Phase 2
- Respiratory Syncytial Virus Infections · Phase 1
- Respiratory Tract Infections · Phase 1
- Rubella · Phase 3
- Salmonella Infections · Phase 2
- Sepsis · Phase 4
- Sexually Transmitted Diseases · Phase 3
- Tetanus · Phase 4
- Typhoid Fever · Phase 3
- Virus Diseases · Phase 3
- Whooping Cough · Phase 4
- Yellow Fever · Phase 3
Mechanism of action
- Streptococcus pneumoniaeImmunity, active
Streptococcus pneumoniae immunity, active
Approval history
- approvedApr 23, 2020
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPilatus PC-7 ↗
- WikipediaMeningococcal vaccine ↗
Also known as
- 4cmenb vaccine
- 4cmenb vaccine
- acwyvax
- bexsero
- bexsero
- conjugated meningococcal acwy-tt
- group c meningococcal polysaccharide-tetansu toxoid conjugate
- gsk3536820a
- mcv-acyw135 vaccine
- menabcwy
- menactra
- menactra
- menacwy
- menacwy conjugate vaccine
- menacwy-crm
- menacwy-crm197
- menacwy-ps
- menacwy vaccine
- men-acyw135
- mencevax
- menc-tt
- meningococcal group a, c, w-135 and y conjugate vaccine
- meningococcal polysaccharide diphtheria toxoid conj.
- meningococcal polysaccharide (serogroups a, c, y and w-135) diphtheria toxoid conjugate vaccine
- meningococcal polysaccharide tetanus protein conjugate
- neisseria meningitidis serogroup a polysaccharide conjugated to tetanus toxoid / neisseria meningitidis serogroup c polysaccharide conjugated to tetanus toxoid /neisseria meningitidis serogroup w-135 polysaccharide conjugated to tetanus toxoid / neisseria meningitidis serogroup y polysaccharide conjugated to tetanus toxoid
- nimenrix
- pc7
- pc7
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07286370 | Phase 2 | Dec 17, 2025 | GlaxoSmithKline |
| NCT07203755 | Phase 1 | Oct 22, 2025 | Government of China, Tianjin Cansino Biotechnology Inc |
| NCT07204457 | Phase 2/Phase 3 (Phase 3) | Oct 15, 2025 | BMI Korea, EyeGene Inc. |
| NCT07135986 | Phase 3 | Sep 26, 2025 | Sanofi |
| NCT06834100 | Phase 3 | Feb 12, 2025 | NPO Petrovax Pharm LLC |
| NCT06700148 | Phase 3 | Dec 30, 2024 | Government of China, Tianjin Cansino Biotechnology Inc |
| NCT06523231 | Phase 2 | Nov 30, 2024 | Kenya Medical Research Institute, LimmaTech Biologics AG |
| NCT06647407 | Phase 1/Phase 2 (Phase 2) | Oct 28, 2024 | Sanofi-Aventis |
| NCT06436274 | Phase 4 | Sep 30, 2024 | Botswana Harvard Aids Institute, Government of Rwanda, Harvard University, Karolinska Institute, National Cancer Institute (NCI), University of the Witwatersrand, University of Washington |
| NCT06337071 | Phase 2 | Mar 20, 2024 | Government of China |
| NCT06284915 | Phase 3 | Mar 19, 2024 | Sanofi-Aventis |
| NCT06226714 | Phase 3 | Mar 1, 2024 | Government of China, Tianjin Cansino Biotechnology Inc |
| NCT06228586 | Phase 3 | Jan 18, 2024 | Sanofi-Aventis |
| NCT06213506 | Phase 2 | Jan 15, 2024 | GlaxoSmithKline, Kwame Nkrumah University of Science and Technology |
| NCT06131554 | Phase 3 | Dec 31, 2023 | Tianjin Cansino Biotechnology Inc |
| NCT06116669 | N/A | Nov 5, 2023 | Jomo Kenyatta University of Agriculture and Technology, Swiss Federal Institute of Technology, University of Oxford |
| NCT06128733 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2023 | Sanofi, Sanofi-Aventis |
| NCT05929651 | Phase 4 | Sep 7, 2023 | Sanofi-Aventis |
| NCT05919472 | N/A | Jul 1, 2023 | JKUAT Nairobi, Jomo Kenyatta University of Agriculture and Technology, Swiss Federal Institute of Technology, University of Oxford |
| NCT05766904 | Phase 3 | May 4, 2023 | Chinese University of Hong Kong |
Showing 20 of 200 trials
Page 1 / 10
Organizations
Research & Development (65)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 48 | 47 | 4 | 2002 |
| Sanofi | For profit | 42 | 38 | 3 | 2002 |
| Novartis | For profit | 36 | 34 | 3 | 2004 |
| Sanofi-Aventis | For profit | 30 | 21 | 3 | 2010 |
| University of Oxford | Academic/Hospital | 9 | 7 | 4 | 2009 |
| Pfizer | For profit | 7 | 7 | 2 | 2002 |
| Government of China | Government | 6 | 1 | 3 | 2013 |
| Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | For profit | 5 | 5 | 3 | 2016 |
| Tianjin Cansino Biotechnology Inc | For profit | 4 | 4 | 2 | 2023 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 2 | 3 | 2016 |
| Serum Institute of India Pvt. Ltd. | For profit | 3 | 3 | 2 | 2017 |
| University of London | Academic/Hospital | 3 | 1 | 2 | 2005 |
| Dalhousie University | Academic/Hospital | 2 | 1 | 1 | 2015 |
| Harvard University | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Janssen Pharmaceutica NV | For profit | 2 | 2 | 1 | 2018 |
| Jomo Kenyatta University of Agriculture and Technology | Academic/Hospital | 2 | 1 | 1 | 2023 |
| Kenya Medical Research Institute | Academic/Hospital | 2 | 0 | 1 | 2019 |
| LimmaTech Biologics AG | For profit | 2 | 2 | 1 | 2019 |
| Merck | For profit | 2 | 2 | 1 | 2006 |
| PATH | Academic/Hospital | 2 | 0 | 2 | 2017 |
65 organizations
Page 1 / 4
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Sanofi-Aventis | For profit | NDA2 | Jan 14, 2005 |
| Sanofi-Aventis | For profit | NDA | Jan 14, 2005 |